UCB SA (OTCMKTS:UCBJY) Short Interest Update

Key Points

• UCB SA experienced a significant 57.1% decrease in short interest in September, dropping from 7,700 shares to 3,300 shares.
• Shares of UCB opened at $145.97 and currently have a consensus rating of "Strong Buy", following upgrades from Zacks Research and Goldman Sachs.
• The company's primary products address various diseases including neurology and immunology issues such as epilepsy and inflammatory diseases.

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 3,300 shares, a decrease of 57.1% from the September 15th total of 7,700 shares. Based on an average trading volume of 64,700 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 64,700 shares, the short-interest ratio is presently 0.1 days.

UCB Trading Down 1.9%

Shares of OTCMKTS:UCBJY opened at $145.97 on Friday. The business's fifty day moving average price is $126.23 and its two-hundred day moving average price is $104.28. UCB has a one year low of $71.16 and a one year high of $151.76.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on UCBJY shares. Zacks Research upgraded UCB from a "hold" rating to a "strong-buy" rating in a report on Friday, August 29th. The Goldman Sachs Group upgraded UCB to a "strong-buy" rating in a report on Wednesday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Strong Buy".

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.